Bausch Health Companies Inc. Stock price

Equities

BHC

CA0717341071

Pharmaceuticals

Market Closed - Nyse 04:00:01 2024-03-18 pm EDT 5-day change 1st Jan Change
9.38 USD +1.96% Intraday chart for Bausch Health Companies Inc. +2.85% +16.96%
Sales 2024 * 9.39B Sales 2025 * 9.21B Capitalization 3.43B
Net income 2024 * 220M Net income 2025 * 11M EV / Sales 2024 * 2.49 x
Net Debt 2024 * 19.91B Net Debt 2025 * 18.33B EV / Sales 2025 * 2.36 x
P/E ratio 2024 *
15 x
P/E ratio 2025 *
469 x
Employees 20,270
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.64%
More Fundamentals * Assessed data
Dynamic Chart
Trump floats billionaire Paulson as potential Treasury chief, Bloomberg reports RE
Bausch Health's Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of Relistor MT
Bausch Health Brief: Salix Pharmaceuticals Announcing a Phase 2 Investigator-Initiated Study of RELISTOR (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma MT
Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma CI
RBC Raises Bausch Health Target to US$9, After Q4 And 2024 Guidance MT
RBC Lifts Price Target on Bausch Health to $9 From $8, Keeps Sector Perform Rating MT
TSX closes at 22-month high powered by tech rally RE
Bausch + Lomb's Likely to Face Market-Related Risks From Spin, RBC Says MT
Toronto Stocks Climb, Loblaw Shares Rise on 4Q Profit, Revenue Growth DJ
Bausch Health's Q4 Loss Narrows, Revenue Increases; Issues 2024 Revenue Outlook; Shares Gain Pre-Bell MT
Transcript : Bausch Health Companies Inc., Q4 2023 Earnings Call, Feb 22, 2024
Bausch Health Reports Q4 2023 Adjusted Earnings of US$406 Million; Revenue of US$2.4 Billion MT
Bausch Health Companies Inc. Reports Goodwill Impairments for the Fourth Quarter Ended December 31, 2023 CI
Bausch Health Companies Inc. Provides Earnings Guidance for the Year 2024 CI
Bausch Health Brief: Adjusted EBITDA Attributable of US$869 million for the quarter, up 6%, and $3.0 billion for the year, in line with prior year MT
More news
1 day+1.96%
1 week+1.63%
Current month-0.11%
1 month+10.22%
3 months+28.85%
6 months+10.09%
Current year+16.96%
More quotes
1 week
9.04
Extreme 9.035
9.43
1 month
8.40
Extreme 8.4
9.90
Current year
7.56
Extreme 7.56
9.90
1 year
5.57
Extreme 5.5703
10.15
3 years
4.00
Extreme 4
34.50
5 years
4.00
Extreme 4
34.80
10 years
4.00
Extreme 4
263.81
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 -
Director of Finance/CFO 51 22-05-23
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member 67 08-07-31
Chairman 68 17-05-31
Director/Board Member 35 21-03-16
More insiders
Date Price Change Volume
24-03-18 9.38 +1.96% 1,195,811
24-03-15 9.2 +1.21% 1,385,517
24-03-14 9.09 -2.05% 1,037,885
24-03-13 9.28 +0.98% 1,075,220
24-03-12 9.19 +0.77% 1,027,329

Delayed Quote Nyse, March 18, 2024 at 04:00 pm EDT

More quotes
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
9.38 USD
Average target price
9.786 USD
Spread / Average Target
+4.33%
Consensus
  1. Stock
  2. Equities
  3. Stock Bausch Health Companies Inc. - Nyse